It's difficult to divorce the ideas of revenue and benefit. We're not talking about open-source software here. We're talking about pharmaceutical products and

It's difficult to divorce the ideas of revenue and benefit. We're not talking about open-source software here. We're talking about pharmaceutical products and getting those to market so that those in need can start benefiting from our advancements. We get our cut of the revenue when our commercial partners are successful. If our technologies can be scaled and make it through trials, then everybody wins. Patients have a safe treatment, the drug companies can recover costs and continue to spend on R&D, and our researchers get their share. Also, we are not bureaucrats. We are former doctors and researchers ourselves. Many of us have worked for startups and are well-connected to the the VC world. We are better-equipped than most to identify partnerships that will lead to a successful transfer of technologies from lab to industry.